Key considerations for maximizing LV and AAV production in transient transfection workflows

Wednesday 9th June 2021

8:00 PDT; 11:00 EDT; 16:00 BST; 17:00 CEST 

Recombinant adeno-associated virus (AAV) and lentivirus (LV) are critical components of gene and cell therapies, which show incredible promise for the treatment of disease. Accordingly, the need for large-scale manufacture of safe and effective viral vectors has never been greater. Here, we present optimization strategies for generating higher AAV and LV titers in both adherent and suspension HEK 293 cells using the TransIT-VirusGEN® Transfection Reagent. In addition, we will introduce LV and AAV enhancers that further increase functional virus titers over previously optimized conditions and expand manufacturing capabilities for gene and cell therapies.

Attendees will learn:

  • Critical parameters for optimizing viral vector production and how small process changes can significantly impact titers 
  • How VirusGEN® Transfection Kits supports gene and cell therapy researchers from R&D through commercial manufacturing
  • How GMP-grade transfection formulations compare in terms of physical titers (GC/mL) and functional titers (TU/mL)
Leisha Kopp
Applications Scientist
Mirus Bio LLC
View Biography
Dr. Beth Larimore
Associate Director, Viral Vector Process Development
Bristol Myers Squibb
View Biography
Dr. Anindya Dasgupta
Director of Vector Development
Expression Therapeutics
View Biography
Nolan Sutherland
Scientist, Molecular and Vector Biology
bluebird bio
View Biography
Elisa Manzotti
CEO and Founder
BioInsights Publishing
View Biography

Registration Details:

Our registration process uses cookies, by submitting this registration form you agree to our cookie policy.

(*) denotes required form field(s)